Vertex Pharmaceuticals’ (VRTX) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a report issued on Friday,Benzinga reports. They currently have a $560.00 target price on the pharmaceutical company’s stock, up from their previous target price of $515.00.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings cut Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 25th. Morgan Stanley initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 1st. They set an “overweight” rating and a $665.00 target price for the company. Royal Bank Of Canada boosted their target price on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $570.83.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $515.44 on Friday. The firm has a market cap of $130.82 billion, a price-to-earnings ratio of 30.00, a PEG ratio of 2.24 and a beta of 0.32. The stock has a fifty day simple moving average of $511.01 and a two-hundred day simple moving average of $473.10. Vertex Pharmaceuticals has a 12 month low of $374.17 and a 12 month high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The company had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.52 earnings per share. On average, equities research analysts forecast that Vertex Pharmaceuticals will post 16.88 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Duncan McKechnie sold 1,541 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total value of $799,779.00. Following the sale, the executive vice president directly owned 11,001 shares in the company, valued at approximately $5,709,519. This trade represents a 12.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 596 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $482.50, for a total transaction of $287,570.00. Following the completion of the transaction, the chief marketing officer directly owned 15,337 shares in the company, valued at approximately $7,400,102.50. The trade was a 3.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,657 shares of company stock valued at $2,346,247 over the last quarter. 0.20% of the stock is owned by corporate insiders.

Institutional Trading of Vertex Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Summit Global Investments acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $3,568,000. Allworth Financial LP lifted its position in shares of Vertex Pharmaceuticals by 414.1% in the fourth quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock valued at $6,363,000 after acquiring an additional 11,306 shares in the last quarter. Calamos Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 77.1% in the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after acquiring an additional 33,917 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth approximately $13,823,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its position in shares of Vertex Pharmaceuticals by 11.9% during the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock worth $15,625,000 after purchasing an additional 3,710 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: JPMorgan reaffirmed its overweight rating and raised its price target to $560 from $515, implying approximately 8.6% potential upside from the referenced price. The target increase signals greater confidence in Vertex’s earnings outlook and pipeline. JPMorgan Vertex analyst rating
• Positive Sentiment: Coverage highlights Vertex’s strong core business and raised guidance as key factors supporting the shares. The company’s latest reported quarter also showed revenue growth of 12.5% year over year to $3.33 billion, ahead of estimates, despite a marginal EPS miss. Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
• Positive Sentiment: Vertex’s approximately $10 billion acquisition of Crinetics Pharmaceuticals is viewed as a potential new growth engine. The transaction gives Vertex an immediate presence in endocrinology and could reduce its long-term dependence on the cystic fibrosis franchise by adding a new commercial platform. Vertex Pharmaceuticals Incorporated: Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
• Neutral Sentiment: Investor conference presentations and a Q2 peer comparison provide additional updates on Vertex’s business and industry position, but the available reports do not identify a new material catalyst beyond the company’s existing financial outlook. Vertex Pharmaceuticals Cantor Fitzgerald Conference Transcript
• Neutral Sentiment: Reported short interest was zero shares, offering no evidence of meaningful short-selling pressure; however, the data appears inconsistent and may be a reporting artifact.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.